- Home
- IGMS vs TWFG Comparison
IGMS vs TWFG Comparison
Compare IGMS & TWFG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IGMS
- TWFG
- Stock Information
- Founded
- IGMS 1993
- TWFG 2001
- Country
- IGMS United States
- TWFG United States
- Employees
- IGMS N/A
- TWFG N/A
- Industry
- IGMS Biotechnology: Pharmaceutical Preparations
- TWFG
- Sector
- IGMS Health Care
- TWFG
- Exchange
- IGMS Nasdaq
- TWFG NYSE
- Market Cap
- IGMS 528.6M
- TWFG 484.1M
- IPO Year
- IGMS 2019
- TWFG 2024
- Fundamental
- Price
- IGMS $7.48
- TWFG $29.26
- Analyst Decision
- IGMS Buy
- TWFG Buy
- Analyst Count
- IGMS 8
- TWFG 8
- Target Price
- IGMS $16.25
- TWFG $31.14
- AVG Volume (30 Days)
- IGMS 213.0K
- TWFG 141.4K
- Earning Date
- IGMS 11-08-2024
- TWFG 11-12-2024
- Dividend Yield
- IGMS N/A
- TWFG N/A
- EPS Growth
- IGMS N/A
- TWFG N/A
- EPS
- IGMS N/A
- TWFG 0.43
- Revenue
- IGMS $2,918,000.00
- TWFG $194,211,000.00
- Revenue This Year
- IGMS $386.95
- TWFG $19.25
- Revenue Next Year
- IGMS N/A
- TWFG $18.42
- P/E Ratio
- IGMS N/A
- TWFG $68.05
- Revenue Growth
- IGMS 57.64
- TWFG 26.18
- 52 Week Low
- IGMS $6.17
- TWFG $21.31
- 52 Week High
- IGMS $22.50
- TWFG $36.50
- Technical
- Relative Strength Index (RSI)
- IGMS 31.94
- TWFG N/A
- Support Level
- IGMS $7.00
- TWFG N/A
- Resistance Level
- IGMS $10.80
- TWFG N/A
- Average True Range (ATR)
- IGMS 1.02
- TWFG 0.00
- MACD
- IGMS -0.10
- TWFG 0.00
- Stochastic Oscillator
- IGMS 10.39
- TWFG 0.00
About IGMS IGM Biosciences Inc.
IGM Biosciences Inc is a biotechnology company engaged in the development of IgM antibody therapeutics for the treatment of cancer, infectious diseases, and autoimmune and inflammatory diseases. Its IgM antibody technology platform is suited for developing T cell engagers, receptor cross-linking agonists, and targeted cytokines. Its product candidate, Aplitabart: An IgM antibody targeting Death Receptor 5 (DR5) proteins, for the treatment of colorectal cancer; Imvotamab: A bispecific for severe systemic lupus erythematosus (SLE) and one for severe rheumatoid arthritis (RA); and IGM-2644: A bispecific T cell engaging IgM antibody targeting CD38 and CD3 proteins, currently planned for evaluation in autoimmune disease.
About TWFG TWFG INC
TWFG Inc is a independent distribution platform for personal and commercial insurance in the United States. It offers all lines of insurance, multiple distribution contract options, M&A services, proprietary virtual assistants, proprietary technology, proprietary premium financing, unlimited continuing education, recognition programs, co-op funding, marketing support and overall lower costs to operate.